Lupus and desoxyribonuclease

被引:20
作者
Lachmann, PJ [1 ]
机构
[1] Ctr Vet Sci, Microbial Immunol Grp, Cambridge CB3 0ES, England
关键词
actin; desoxyribonuclease; dexamethasone; LE cell; nucleosomes; treatment trial;
D O I
10.1191/0961203303lu357xx
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The dominant autoantigen in SLE is the nucleosome and immune complexes involving nucleosomes are the major cause of tissue damage. Nucleosomes can be broken down in vivo with Desoxyribonuclease 1. DNase 1 from humans and mice is inhibited by actin and it is proposed that the release of platelet actin at inflammatory sites is one mechanism which causes nucleosomes to become antigenic. Rats whose DNase 1 is not inhibited by actin do not get lupus. Treatment of NZB/W mice with recombinant DNase slows the onset of their disease if given early and improves the renal disease if given later. This disease can also be entirely prevented by treatment with dexamethasone. Mice whose DNase 1 gene is knocked out are known to develop lupus and to be otherwise normal. DNase 1 especially in its mutant actin and salt resistant forms remains an attractive candidate for the treatment of SLE.
引用
收藏
页码:202 / 206
页数:5
相关论文
共 30 条
[21]  
LAZARUS RA, 2002, RILEY ENCY MOL MED, P1025
[22]   The treatment of systemic lupus erythematosus (SLE) in NZB/W F-1 hybrid mice; Studies with recombinant murine DNase and with dexamethasone [J].
Macanovic, M ;
Sinicropi, D ;
Shak, S ;
Baughman, S ;
Thiru, S ;
Lachmann, PJ .
CLINICAL AND EXPERIMENTAL IMMUNOLOGY, 1996, 106 (02) :243-252
[23]   LABSORPTION DU FACTEUR LE PAR DES NOYAUX CELLULAIRES ISOLES [J].
MIESCHER, P ;
FAUCONNET, M .
EXPERIENTIA, 1954, 10 (06) :252-254
[24]   Features of systemic lupus erythematosus in Dnase1-deficient mice [J].
Napirei, M ;
Karsunky, H ;
Zevnik, B ;
Stephan, H ;
Mannherz, HG ;
Möröy, T .
NATURE GENETICS, 2000, 25 (02) :177-181
[25]   Engineering hyperactive variants of human deoxyribonuclease I by altering its functional mechanism [J].
Pan, CQ ;
Lazarus, RA .
BIOCHEMISTRY, 1997, 36 (22) :6624-6632
[26]  
Pickering M C, 2000, Adv Immunol, V76, P227
[27]   RECOMBINANT HUMAN DNASE-I REDUCES THE VISCOSITY OF CYSTIC-FIBROSIS SPUTUM [J].
SHAK, S ;
CAPON, DJ ;
HELLMISS, R ;
MARSTERS, SA ;
BAKER, CL .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1990, 87 (23) :9188-9192
[28]   Engineering actin-resistant human DNase I for treatment of cystic fibrosis [J].
Ulmer, JS ;
Herzka, A ;
Toy, KJ ;
Baker, DL ;
Dodge, AH ;
Sinicropi, D ;
Shak, S ;
Lazarus, RA .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (16) :8225-8229
[29]  
WALPORT MJ, 2001, 6 INT LUP C BARC
[30]  
ZHANG W, 1995, CLIN EXP IMMUNOL, V101, P507